{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:34:33Z","timestamp":1786988073680,"version":"build-2736575974"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100017688","name":"Guangdong Provincial Key Laboratory of Construction Foundation","doi-asserted-by":"publisher","award":["2023B1212060022"],"award-info":[{"award-number":["2023B1212060022"]}],"id":[{"id":"10.13039\/501100017688","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972824"],"award-info":[{"award-number":["81972824"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2020A1515011513"],"award-info":[{"award-number":["2020A1515011513"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ejmech.2025.118141","type":"journal-article","created":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T14:51:58Z","timestamp":1757170318000},"page":"118141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Aurora A degradation by HSP90 interactome-mediating PROTACs in A549 and paclitaxel-resistant A549\u00a0cells"],"prefix":"10.1016","volume":"300","author":[{"given":"Xiao-Yi","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Xuan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Yao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-Fan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0089-0907","authenticated-orcid":false,"given":"Gui","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118141_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ccm.2019.10.001","article-title":"Lung cancer 2020: epidemiology, etiology, and prevention","volume":"41","author":"Bade","year":"2020","journal-title":"Clin. Chest Med."},{"key":"10.1016\/j.ejmech.2025.118141_bib2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.semcancer.2023.05.008","article-title":"Advancements in small cell lung cancer","volume":"93","author":"Lee","year":"2023","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ejmech.2025.118141_bib3","doi-asserted-by":"crossref","first-page":"16195","DOI":"10.1021\/acs.jmedchem.4c01026","article-title":"Evaluation of efficiency of liposome-entrapped iridium(III) complexes inhibiting tumor growth in vitro and in vivo","volume":"67","author":"Hu","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118141_bib4","doi-asserted-by":"crossref","first-page":"15176","DOI":"10.1039\/D4DT01677G","article-title":"Anticancer activity and mechanism studies of photoactivated iridium(III) complexes toward lung cancer A549 cells","volume":"53","author":"Zhou","year":"2024","journal-title":"Dalton Trans"},{"key":"10.1016\/j.ejmech.2025.118141_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinorgbio.2021.111550","article-title":"Iridium(III)-BBIP complexes induce apoptosis via PI3K\/AKT\/mTOR pathway and inhibit A549 lung tumor growth in vivo","volume":"223","author":"Zhou","year":"2021","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.ejmech.2025.118141_bib6","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3390\/curroncol32040206","article-title":"Unveiling the synergistic potential: bispecific antibodies in conjunction with chemotherapy for advanced non-small-cell lung cancer treatment","volume":"32","author":"Khan","year":"2025","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.ejmech.2025.118141_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116558","article-title":"Design, synthesis and biological evaluation of 5-amino-1H-pyrazole-4-carboxamide derivatives as pan-FGFR covalent inhibitors","volume":"275","author":"Deng","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118141_bib8","doi-asserted-by":"crossref","first-page":"6905","DOI":"10.1021\/acs.jmedchem.3c00319","article-title":"Design, synthesis, and evaluation of (R)-8-((tetrahydrofuran-2-yl)methyl)pyrido[2,3-d]pyrimidin-7-ones as novel selective ACK1 Inhibitors to combat acquired resistance to the third-generation EGFR Inhibitor","volume":"66","author":"Li","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118141_bib9","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/cas.15229","article-title":"LS-106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo","volume":"113","author":"Liu","year":"2022","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejmech.2025.118141_bib10","doi-asserted-by":"crossref","first-page":"7302","DOI":"10.1021\/acs.jmedchem.9b00576","article-title":"Structure-based design of 5-methylpyrimidopyridone derivatives as new wild-type sparing inhibitors of the epidermal growth factor receptor triple mutant (EGFR(L858R\/T790M\/C797S))","volume":"62","author":"Shen","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118141_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111663","article-title":"Activity of 2,6,9-trisubstituted purines as potent PDGFR\u03b1 kinase inhibitors with antileukaemic activity","volume":"182","author":"\u0158ezn\u00ed\u010dkov\u00e1","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118141_bib12","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.tips.2017.05.003","article-title":"Aurora A kinase is a priority pharmaceutical target for the treatment of cancers","volume":"38","author":"Damodaran","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2025.118141_bib13","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1002\/med.21399","article-title":"Aurora-A kinase: a potent oncogene and target for cancer therapy","volume":"36","author":"Yan","year":"2016","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2025.118141_bib14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12943-020-01305-3","article-title":"Targeting AURKA in cancer: molecular mechanisms and opportunities for cancer therapy","volume":"20","author":"Du","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2025.118141_bib15","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.ejmech.2017.12.082","article-title":"Synthesis and biological evaluation of aurora kinases inhibitors based on N-trisubstituted pyrimidine scaffold","volume":"145","author":"Long","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118141_bib16","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.ejmech.2018.08.053","article-title":"Structure-based drug design: synthesis and biological evaluation of quinazolin-4-amine derivatives as selective Aurora A kinase inhibitors","volume":"157","author":"Long","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118141_bib17","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejmech.2014.03.027","article-title":"Design, synthesis and bioevaluation of N-trisubstituted pyrimidine derivatives as potent Aurora A kinase inhibitors","volume":"78","author":"Luo","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118141_bib18","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ejca.2021.06.012","article-title":"Phase 1 study combining alisertib with nab-paclitaxel in patients with advanced solid malignancies","volume":"154","author":"Lim","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejmech.2025.118141_bib19","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1200\/JCO.18.00899","article-title":"Randomized phase iii study of alisertib or investigator's choice (selected single agent) in patients with relapsed or refractory peripheral T-cell lymphoma","volume":"37","author":"O'Connor","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.118141_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.115033","article-title":"Targeted AURKA degradation: towards new therapeutic agents for neuroblastoma","volume":"247","author":"Rishfi","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118141_bib21","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.3324\/haematol.2019.220012","article-title":"A phase 1 trial of alisertib and romidepsin for relapsed\/refractory aggressive B-cell and T-cell lymphomas","volume":"105","author":"Strati","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.ejmech.2025.118141_bib22","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ccell.2016.12.005","article-title":"MYC drives progression of small cell lung cancer to a variant neuroendocrine subtype with vulnerability to Aurora kinase inhibition","volume":"31","author":"Mollaoglu","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2025.118141_bib23","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1182\/blood-2009-11-251074","article-title":"Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state","volume":"116","author":"Den Hollander","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.118141_bib24","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-45272-3","article-title":"Computational completion of the Aurora interaction region of N-Myc in the Aurora A kinase complex","volume":"13","author":"Altiner","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2025.118141_bib25","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41422-020-00397-2","article-title":"Oncogenic AURKA-enhanced N(6)-methyladenosine modification increases DROSHA mRNA stability to transactivate STC1 in breast cancer stem-like cells","volume":"31","author":"Peng","year":"2021","journal-title":"Cell Res."},{"key":"10.1016\/j.ejmech.2025.118141_bib26","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.jid.2017.01.021","article-title":"AURKA overexpression is driven by FOXM1 and MAPK\/ERK activation in melanoma cells harboring BRAF or NRAS mutations: impact on melanoma prognosis and therapy","volume":"137","author":"Puig-Butille","year":"2017","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.ejmech.2025.118141_bib27","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1038\/onc.2016.490","article-title":"FOXM1 recruits nuclear Aurora kinase A to participate in a positive feedback loop essential for the self-renewal of breast cancer stem cells","volume":"36","author":"Yang","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2025.118141_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2024.103137","article-title":"Meningioma achieves malignancy and erastin-induced ferroptosis resistance through FOXM1-AURKA-NRF2 axis","volume":"72","author":"Ye","year":"2024","journal-title":"Redox Biol."},{"key":"10.1016\/j.ejmech.2025.118141_bib29","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/s41589-020-00652-y","article-title":"PROTAC-mediated degradation reveals a non-catalytic function of Aurora-A kinase","volume":"16","author":"Adhikari","year":"2020","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.118141_bib30","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1016\/j.apsb.2023.03.013","article-title":"Emerging roles of Aurora-A kinase in cancer therapy resistance","volume":"13","author":"Zheng","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2025.118141_bib31","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13045-020-00885-3","article-title":"Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy","volume":"13","author":"Li","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2025.118141_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112981","article-title":"Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: recent progress and future challenges","volume":"210","author":"Zeng","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118141_bib33","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.118141_bib34","article-title":"Novel, highly potent PROTACs targeting Aurora-A kinase","volume":"2","author":"Jelena","year":"2022","journal-title":"Curr. Res. Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.118141_bib35","article-title":"A temporal PROTAC cocktail-mediated sequential degradation of AURKA abrogates acute myeloid leukemia stem cells","volume":"9","author":"Liu","year":"2022","journal-title":"Adv. Sci."},{"key":"10.1016\/j.ejmech.2025.118141_bib36","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s42003-021-02158-2","article-title":"Selective targeting of non-centrosomal AURKA functions through use of a targeted protein degradation tool","volume":"4","author":"Wang","year":"2021","journal-title":"Commun. Biol."},{"key":"10.1016\/j.ejmech.2025.118141_bib37","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrm.2017.20","article-title":"The HSP90 chaperone machinery","volume":"18","author":"Schopf","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.118141_bib38","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s10495-019-01577-1","article-title":"Inhibitors of HSP90 in melanoma","volume":"25","author":"Mielczarek-Lewandowska","year":"2020","journal-title":"Apotosis"},{"key":"10.1016\/j.ejmech.2025.118141_bib39","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/s41419-022-05373-9","article-title":"HSP90 mediates the connection of multiple programmed cell death in diseases","volume":"13","author":"Peng","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2025.118141_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1436973","article-title":"HSP90 multi-functionality in cancer","volume":"15","author":"Albakova","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2025.118141_bib41","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s12032-022-01777-x","article-title":"Combination of AURKA inhibitor and HSP90 inhibitor to treat breast cancer with AURKA overexpression and TP53 mutations","volume":"39","author":"Wang","year":"2022","journal-title":"Med. Oncol."},{"key":"10.1016\/j.ejmech.2025.118141_bib42","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/hon.3110","article-title":"Heat shock protein 90 inhibitors induce cell differentiation via the ubiquitin-dependent aurora kinase A degradation in a MPLW515L mouse model of primary myelofibrosis","volume":"41","author":"Wang","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2025.118141_bib43","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/15384101.2020.1867790","article-title":"DNA-PKcs inhibition impairs HDAC6-mediated HSP90 chaperone function on Aurora A and enhances HDACs inhibitor-induced cell killing by increasing mitotic aberrant spindle assembly","volume":"20","author":"Yu","year":"2021","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ejmech.2025.118141_bib44","first-page":"117","article-title":"Inhibitors of histone deacetylases induce tumor-selective cytotoxicity through modulating Aurora-A kinase","volume":"86","author":"Park","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118141_bib45","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1021\/acs.jmedchem.2c01648","article-title":"Targeted protein degradation Induced by HEMTACs based on HSP90","volume":"66","author":"Li","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118141_bib46","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/128_2012_356","article-title":"Hsp90: structure and function","volume":"328","author":"Jackson","year":"2013","journal-title":"Topics Curr. Chem."},{"key":"10.1016\/j.ejmech.2025.118141_bib47","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1021\/acs.jcim.1c01036","article-title":"Impact of PROTAC linker plasticity on the solution conformations and dissociation of the ternary complex","volume":"62","author":"Weerakoon","year":"2022","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2025.118141_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116520","article-title":"Application and challenges of nitrogen heterocycles in PROTAC linker","volume":"273","author":"Li","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118141_bib49","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ymthe.2022.11.011","article-title":"PROTAC therapy as a new targeted therapy for lung cancer","volume":"31","author":"Li","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejmech.2025.118141_bib50","doi-asserted-by":"crossref","first-page":"7614","DOI":"10.1158\/1078-0432.CCR-11-1536","article-title":"Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays","volume":"17","author":"Manfredi","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118141_bib51","doi-asserted-by":"crossref","first-page":"16712","DOI":"10.1021\/acs.jmedchem.4c01518","article-title":"Heatshock protein 90 interactome-mediated proteolysis targeting chimera (HIM-PROTAC) degrading glutathione peroxidase 4 to trigger ferroptosis","volume":"67","author":"Dong","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118141_bib52","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1002\/ijc.22154","article-title":"Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells","volume":"119","author":"Yang","year":"2006","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejmech.2025.118141_bib53","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1007\/s13277-013-1393-8","article-title":"Aurora-A: a potential DNA repair modulator","volume":"35","author":"Wang","year":"2014","journal-title":"Tumor Biol."},{"key":"10.1016\/j.ejmech.2025.118141_bib54","doi-asserted-by":"crossref","first-page":"8998","DOI":"10.1158\/0008-5472.CAN-08-2658","article-title":"Aurora kinase A inhibition leads to p73-dependent apoptosis in p53-deficient cancer cells","volume":"68","author":"Dar","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118141_bib55","doi-asserted-by":"crossref","first-page":"759","DOI":"10.3858\/emm.2010.42.11.077","article-title":"Suppression of Aurora-A oncogenic potential by c-Myc downregulation","volume":"42","author":"Yang","year":"2010","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.ejmech.2025.118141_bib56","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1089\/thy.2018.0183","article-title":"C-Myc is a major determinant for antitumor activity of Aurora A kinase inhibitor MLN8237 in thyroid cancer","volume":"28","author":"Li","year":"2018","journal-title":"Thyroid"},{"key":"10.1016\/j.ejmech.2025.118141_bib57","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/1476-4598-9-205","article-title":"Regulation of the Aurora-A gene following topoisomerase I inhibition: implication of the Myc transcription factor","volume":"9","author":"Courapied","year":"2010","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2025.118141_bib58","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1470-2045(15)70051-3","volume":"16","author":"Melichar","year":"2015","journal-title":"Lancet Oncol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425009067?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425009067?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T22:55:47Z","timestamp":1772837747000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425009067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":58,"alternative-id":["S0223523425009067"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118141","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aurora A degradation by HSP90 interactome-mediating PROTACs in A549 and paclitaxel-resistant A549\u00a0cells","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118141","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118141"}}